SAB Biotherapeutics's total assets for Q4 2025 were $172.81M, a decrease of -5.80% from the previous quarter. SABS total liabilities were $21.32M for the fiscal quarter, a 16.01% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.